ClinicalTrials.gg
CompletedNCT07849894Updated Sep 30, 2026

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.

A Phase 1 interventional study of UCB0159 and Placebo in Mild to Moderate Psoriasis and Healthy Volunteers, sponsored by UCB Biopharma SRL. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Registered 9 years 3 months after the study started (first participant enrolled Jun 2017, registered Sep 2026).
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Psoriasis by UCB S.A. — 1 open to participants now, 2 under way, 2 of them phase 3. Psoriasis · UCB S.A..

Enrollment
19th of 25
54 · median 176
Started
2017
with 3 others
Phase 1
3 of 26
none open now
Registered
26th of 26
by date

Among the 26 studies in Psoriasis by UCB S.A., this one is the 19th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2017, is one of 3 in phase 1, and was the 26th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 26 studies in Psoriasis by UCB S.A. is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Psoriasis by UCB S.A., or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and pharmacokinetics of UCB0159 administered in participants with mild to moderate plaque psoriasis and evaluate single dose pharmacokinetics and safety of UCB0159 in healthy participants.

03

Conditions studied

  • Mild to Moderate Psoriasis
  • Healthy Volunteers

Browse trials for

Keywords

  • Mild to moderate Psoriasis
  • Healthy volunteers
  • UCB0159
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

All Participants (healthy and participants with mild to moderate plaque PSO):

  • Participant is male or female, aged >=18 years to \<=70 years at Screening.
  • Participant is considered reliable and capable of adhering to the protocol.
  • Female participants must either be , permanently sterilized or congenitally sterile. Female participants of must agree to use a highly effective method of during the study period (from dosing until the Safety follow up (SFU) Visit) and for a period of 6 months after dosing of medicinal product (IMP).
  • Male Participant confirms that during the study period and for a period of 6 months, or, when having sexual intercourse with a woman of childbearing potential, a method of efficient contraception will be used, including a barrier (eg, condom without spermicide or fat- or oil containing lubricants) AND an additional highly effective contraceptive method (as listed below) by the female partner.
  • Participant has a between 18 and \<=35kilograms (kg)/m\^2 and a minimum body weight of 45kg (female participants) and 50kg (male participants) at Screening.
  • Participant is in good physical and mental health, in the opinion of the Investigator, determined on the basis of medical history and general clinical examination at Screening and at Baseline.

Participants with mild to moderate plaque Psoriasis:

  • Confirmed diagnosis of mild to moderate plaque-type Psoriasis for at least 6 months involving \<10 percent (%) of body surface area (BSA) (excluding the scalp).
  • Minimum of 2 psoriatic lesions with at least 1 plaque in a site suitable for .

Exclusion Criteria: All Participants (healthy and participants with mild to moderate plaque PSO):

  • Participant has received an IMP within the last 3 months or 5 half-lives prior to Screening, whichever is longer.
  • Participant has a known reaction to any components of the IMP (polysorbate 80, histidine, and/or proline).
  • Participant has donated more than 400 milliliters (mL) of blood or blood products within 90 days prior to check in (Day -2) or plans to donate blood during the study.
  • Participant has an active or recurrent infection (eg, sepsis, pneumonia, or abscess) or has had a serious or opportunistic infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to IMP administration.
  • Participant with known active tuberculosis (TB) disease, with a past history of active TB involving any organ system, participant with current or history of nontuberculous mycobacterial (NTMB) infection despite prior or current therapy, participants at high risk of acquiring TB infection.
  • Participant with latent TB infection (LTBI).
  • Participant has received within 8 weeks prior to Screening or intends to have such a vaccination during the course of the study or within 12 weeks after the dose of study drug.
  • Participant has a positive surface antigen or positive antibody result within 3 months prior to Screening.
  • Participant has a positive test for (HIV) antibody.

Participants with mild to moderate plaque Psoriasis:

  • Participant has received systemic nonbiologic PSO therapy (methotrexate [MTX], , or cyclophosphamide), phytotherapy, or psoralen plus ultraviolet A (PUVA)/ultraviolet A (UVA) phototherapy within 4 weeks prior to Screening.
  • Participant has received alefacept within 24 months prior to Screening.
  • Participant has received treatment with biological agents other than alefacept, eg, adalimumab, efalizumab, etanercept, infliximab, ustekinumab, or bimekizumab within 12 weeks prior to Screening.
  • Participant has a history or current evidence of disease other than PSO
  • Participant has any other acute or chronic illness which, in the opinion of the Investigator or Study Physician, could pose a threat or harm to the Participant.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    UCB0159 dosing regimen

    Participants randomized into the UCB0159 dosing regimen will receive different dosages of UCB0159 at pre-defined time points.

    Drug: UCB0159

  • Placebo comparator
    Placebo

    Participants randomized into the Placebo arm will receive placebo at pre-defined time points to maintain the blinding.

    Other: Placebo

Interventions

  • DrugUCB0159

    Different dosages will be provided.

  • OtherPlacebo

    Placebo will be provided matching UCB0159 to maintain the blinding.

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events from the Screening Visit through the Safety-Follow Up Visit

    An AE is any untoward medical occurrence in a patient or clinical study participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a investigational medicinal product, whether or not related to the investigational medicinal product.

    Time frame: From Screening Visit through Safety Follow-Up Visit (up to Day 85)

  2. Cmax: maximum serum concentration of UCB0159

    Cmax: maximum serum concentration of UCB0159

    Time frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)

  3. tmax: time to reach maximum serum concentration of UCB0159

    tmax: time to reach maximum serum concentration of UCB0159

    Time frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)

  4. AUC(0-t): Area under the UCB0159 concentration-time curve from time 0 to time t, time of last quantifiable concentration

    AUC(0-t): Area under the UCB0159 concentration-time curve from time 0 to time t, time of last quantifiable concentration

    Time frame: Samples will be collected predose (Day -1) and postdose at predefined time points (Day 1 to Day 85)

07

Study locations

2 sites
  • PS0019 2
    Berlin, Germany
  • PS0019 1
    Harrow, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Dec 2018, 17 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 17 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
Jun 23, 2017
Primary completionActual
Dec 8, 2018
CompletionActual
Dec 8, 2018
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849894
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Jun 23, 2017
Primary completion
Dec 8, 2018
Completion
Dec 8, 2018
Last update
Sep 30, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion